APA (7th ed.) Citation

BJ, B., W, X., G, B., LXT, N., M, V., A, V., . . . EM, S. (2025). Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML. Journal of hematology & oncology, 18(1), 73. https://doi.org/10.1186/s13045-025-01724-z

Chicago Style (17th ed.) Citation

BJ, Ball, et al. "Phase I First-in-human Dose Escalation Study of the Oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 Inhibitor BTX A51 in Advanced MDS and AML." Journal of Hematology & Oncology 18, no. 1 (2025): 73. https://doi.org/10.1186/s13045-025-01724-z.

MLA (9th ed.) Citation

BJ, Ball, et al. "Phase I First-in-human Dose Escalation Study of the Oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 Inhibitor BTX A51 in Advanced MDS and AML." Journal of Hematology & Oncology, vol. 18, no. 1, 2025, p. 73, https://doi.org/10.1186/s13045-025-01724-z.